In September, health experts from around the globe gathered at the 2018 World Conference on Lung Cancer in Toronto. We compiled a list of 8 key findings presented at the event.
Mean changes in hematologic indices found similar regardless of same-day or prior administration of B12 supplementation in patients receiving pemetrexed for NSCLC or pleural mesothelioma.
Immune checkpoint inhibitor pneumonitis is a potentially serious complication that may occur more in patients with lung cancer than previously suspected.
Annual number of deaths expected to continue to decrease despite growth, aging of US population.
The use of angiotensin-converting enzyme inhibitors is associated with an increased risk for lung cancer compared with angiotensin receptor blockers.
Surgical invasiveness might play a role in the odds of becoming a long-term opioid user after early-stage lung cancer surgery.
Prediction tool may help physicians better personalize screening discussions with patients.
Crossover in sex-specific rates among US non-Hispanic whites born since 1965
A multi-analyte blood test, CancerSEEK, can detect 8 common cancer types, with high sensitivity and specificity.
Nivolumab treatment for non-small-cell lung cancer may induce successful depletion of HIV reservoir.
Vitamin B supplements are not chemopreventive and may increase cancer risk in men.
The risk of lung cancer was reduced for high intake of polyunsaturated fat.
An estimated 900,000 veterans of a population of 6.7 million VHA patients met the criteria for LCS.
Recent studies show that nivolumab was associated with increased overall survival rate when compared to docetaxel in patients with advanced squamous cell non-small cell lung cancer.
The number of incidental pulmonary nodules has increased though the number of lung cancer cases remained stable.
CMS announced it has drafted a reimbursement proposal to cover annual computed tomography (CT) scans for high-risk patients.
The government is evaluating the risks and benefits associated with low-dose CT scans and potential coverage changes for Medicaid patients.
Low-dose computed tomography screening is a low-cost strategy that can help the estimated 4.9 million Medicare patients that could meet criteria for lung cancer.
Further research into smoking cessation within screening programs may continue to decrease smoking rates.
The FDA has granted accelerated approval to Zykadia (ceritinib) in patients with metastatic ALK-positive non-small cell lung cancer who have progressed on or are intolerant to crizotinib.
Screening urged for adults aged 55 to 80 years with 30 pack-year history who smoke or recently quit